Stock VNRX VOLITIONRX LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials VolitionRx Limited

Equities

VNRX

US9286611077

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.9137 USD +2.65% Intraday chart for VolitionRx Limited +48.33% +27.43%
Apr. 26 VolitionRx Limited Announces Board Changes CI
Apr. 23 VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 194.8 187.5 168.1 139.8 56.42 74.99 - -
Enterprise Value (EV) 1 181.4 187.5 168.1 139.8 56.42 66.09 93.39 95.09
P/E ratio -11.6 x -8.64 x -6.16 x -4.42 x -1.43 x -2.25 x -2.83 x -15.2 x
Yield - - - - - - - -
Capitalization / Revenue 11,391 x 13,960 x 1,867 x 456 x 72.8 x 20.6 x 4.55 x 1.23 x
EV / Revenue 10,606 x 13,960 x 1,867 x 456 x 72.8 x 18.2 x 5.67 x 1.56 x
EV / EBITDA -11.5 x -9.13 x - -5.04 x -1.73 x -1.98 x -3.43 x -16.4 x
EV / FCF - -10.2 x -7.7 x - - -2.11 x -3.58 x -146 x
FCF Yield - -9.82% -13% - - -47.3% -27.9% -0.68%
Price to Book 13.7 x - - - - - - -
Nbr of stocks (in thousands) 41,092 48,198 53,536 57,521 78,686 82,068 - -
Reference price 2 4.740 3.890 3.140 2.430 0.7170 0.9137 0.9137 0.9137
Announcement Date 2/20/20 3/22/21 3/30/22 3/15/23 3/25/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.0171 0.0134 0.09 0.3064 0.7753 3.632 16.48 60.96
EBITDA 1 -15.83 -20.53 - -27.73 -32.55 -33.4 -27.2 -5.8
EBIT 1 -16.04 -21.25 -28.33 -31.78 -35.99 -35.72 -31.01 -4.105
Operating Margin -93,818.25% -158,211.62% -31,467.21% -10,372.42% -4,641.78% -983.3% -188.14% -6.73%
Earnings before Tax (EBT) 1 -16.1 -20.4 -26.99 -30.6 -35.68 -36.37 -31.18 -4.272
Net income 1 -16.1 -20.35 -26.81 -30.27 -35.32 -36.22 -31.98 -5.072
Net margin -94,146.55% -151,542.22% -29,780.84% -9,879.17% -4,555.54% -997.14% -194.05% -8.32%
EPS 2 -0.4100 -0.4500 -0.5100 -0.5500 -0.5000 -0.4060 -0.3225 -0.0600
Free Cash Flow 1 - -18.41 -21.83 - - -31.25 -26.1 -0.65
FCF margin - -137,046.17% -24,241.98% - - -860.29% -158.36% -1.07%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/20/20 3/22/21 3/30/22 3/15/23 3/25/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 0.0255 0.0142 0.1142 0.0398 0.0327 0.1197 0.1498 0.2163 0.1652 0.244 0.3895 0.635 0.9938 1.617 1.3
EBITDA 1 - - - - - - -8.079 - -7.819 -7.978 -8.3 -8.6 -8.4 -8 -
EBIT 1 -7.562 -8.785 -7.677 -8.099 -7.993 -8.011 -9.045 -9.549 -8.653 -8.741 -8.883 -8.932 -8.869 -8.741 -7.9
Operating Margin -29,679.32% -61,692.56% -6,721.81% -20,376.05% -24,435.83% -6,691.16% -6,037.67% -4,414.52% -5,237.61% -3,582.64% -2,280.49% -1,406.69% -892.45% -540.65% -607.69%
Earnings before Tax (EBT) 1 -7.182 -8.21 -7.718 -7.732 -7.812 -7.336 -8.873 -9.551 -8.453 -8.8 -8.933 -9.033 -9.1 -9.133 -7.9
Net income 1 -7.136 -7.933 -7.634 -7.65 -7.743 -7.242 -8.78 -9.471 -8.37 -8.698 -8.982 -9.057 -9.07 -8.944 -7.9
Net margin -28,007.97% -55,710.04% -6,684.2% -19,244.53% -23,671.57% -6,049.2% -5,860.46% -4,378.43% -5,066.46% -3,565.29% -2,305.94% -1,426.37% -912.7% -553.22% -607.69%
EPS 2 -0.1300 -0.1500 -0.1400 -0.1400 -0.1400 -0.1300 -0.1500 -0.1400 -0.1100 -0.1100 -0.1100 -0.1075 -0.1075 -0.0950 -0.0700
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/10/21 3/30/22 5/11/22 8/10/22 11/14/22 3/15/23 5/10/23 8/14/23 11/14/23 3/25/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - 18.4 20.1
Net Cash position 1 13.4 - - - - 8.9 - -
Leverage (Debt/EBITDA) - - - - - - -0.6765 x -3.466 x
Free Cash Flow 1 - -18.4 -21.8 - - -31.3 -26.1 -0.65
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 0.3500 - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 0.51 1.94 0.97 - - 0.97 1.87 3.5
Capex / Sales 2,989.88% 14,453.16% 1,081.25% - - 26.61% 11.33% 5.74%
Announcement Date 2/20/20 3/22/21 3/30/22 3/15/23 3/25/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for VolitionRx Limited

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9137 USD
Average target price
3.725 USD
Spread / Average Target
+307.68%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

1st Jan change Capi.
VOLITIONRX LIMITED Stock VolitionRx Limited
+27.43% 74.99M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.45% 10.82B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+43.17% 3.25B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-35.86% 2.11B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-17.21% 2.08B
VERACYTE, INC. Stock Veracyte, Inc.
-29.81% 1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+17.56% 1.02B
SEEGENE, INC. Stock Seegene, Inc.
-4.37% 733M
CAREDX, INC Stock CareDx, Inc
-37.00% 391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-46.94% 377M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. VNRX Stock
  4. Financials VolitionRx Limited